Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chronic lymphocytic leukaemia Australasian consensus practice statement.
Anderson MA, Bennett R, Badoux X, Best G, Chia N, Cochrane T, Cull G, Crassini K, Harrup R, Jackson S, Kuss B, Lasica M, Lew TE, Marlton P, Opat S, Palfreyman E, Polizzotto MN, Ratnasingam S, Seymour JF, Soosapilla A, Talaulikar D, Tam CS, Weinkove R, Wight J, Mulligan SP. Anderson MA, et al. Intern Med J. 2023 Sep;53(9):1678-1691. doi: 10.1111/imj.16207. Intern Med J. 2023. PMID: 37743239 Free article.
Clobazam for seizure prophylaxis during busulfan chemotherapy.
Schwarer AP, Opat SS, Watson AL, Cole-Sinclair MF. Schwarer AP, et al. Among authors: opat ss. Lancet. 1995 Nov 4;346(8984):1238. doi: 10.1016/s0140-6736(95)92951-7. Lancet. 1995. PMID: 7475702 Clinical Trial. No abstract available.
CD30:CD30 ligand interactions in the immune response.
Opat S, Gaston JS. Opat S, et al. Autoimmunity. 2000;33(1):45-60. doi: 10.3109/08916930108994109. Autoimmunity. 2000. PMID: 11204253 Free article. Review. No abstract available.
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.
Baggio D, Wellard C, Chung E, Talaulikar D, Keane C, Opat S, Giri P, Minson A, Cheah CY, Armytage T, Lee D, Chong G, Johnston A, Cochrane T, Waters N, Hamad N, Wood EM, Hawkes EA. Baggio D, et al. Leuk Lymphoma. 2023 Mar;64(3):621-627. doi: 10.1080/10428194.2022.2157676. Epub 2022 Dec 21. Leuk Lymphoma. 2023. PMID: 38376128
Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control study.
Odutola MK, van Leeuwen MT, Bruinsma FJ, Benke G, Turner MC, Trotman J, Turner J, Seymour JF, Prince HM, Milliken ST, Tiley C, Hertzberg M, Roncolato F, Opat S, Lindeman R, Verner E, Underhill CR, Cardis E, Giles G, Vajdic CM. Odutola MK, et al. Occup Environ Med. 2023 Oct;80(10):599-602. doi: 10.1136/oemed-2023-108949. Epub 2023 Sep 18. Occup Environ Med. 2023. PMID: 37722828 Free PMC article.
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis.
Song Y, Zhou K, Zou D, Li D, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Zhou D, Tam CS, Simpson D, Wang M, Phillips TJ, Opat S, Fang C, Sun S, Zhu J. Song Y, et al. Cancer Med. 2023 Sep;12(18):18643-18653. doi: 10.1002/cam4.6473. Epub 2023 Sep 14. Cancer Med. 2023. PMID: 37705497 Free PMC article.
136 results